Zhengkang Liang

Trastuzumab deruxtecan (T-DXd) demonstrated significantly improved efficacy over trastuzumab emtansine (T-DM1) in DESTINY-Breast03 (median follow-up, 28 months). We report updated efficacy and safety analyses, including secondary and exploratory efficacy endpoints (median follow-up, 41 months) of DESTINY-Breast03. Patients with advanced HER2-positive metastatic breast cancer previously treated with taxane and trastuzumab were randomized to T-DXd (5.4 mg per kg (261 patients)) or T-DM1 (3.6 mg per kg (263 patients)). The primary endpoint was progression-free survival (PFS) by blinded independent central review and was previously reported. The key secondary endpoint was overall survival (OS). Other secondary endpoints included objective response rate, duration of response and PFS (all by investigator assessment) and safety. At data cutoff, 20 November 2023, median PFS by investigator assessment was 29.0 versus 7.2 months (hazard ratio (HR), 0.30; 95% confidence interval (CI), 0.24-0.38), the 36-month PFS rate was 45.7% versus 12.4% and median OS was 52.6 versus 42.7 months (HR, 0.73; 95% CI, 0.56-0.94) with T-DXd versus T-DM1, respectively. Treatment-emergent adverse events were consistent with the previous analyses. No new instances of grade ≥3 interstitial lung disease or pneumonitis occurred (all grade rate, 16.7% (T-DXd) versus 3.4% (T-DM1)). With longer follow-up, T-DXd continued to demonstrate superior efficacy over T-DM1 with a manageable safety profile. ClinicalTrials.gov registration: NCT03529110 .

Abstract Migratory behaviour in insects correlates with reproductive development in females, and migration often occurs during the pre‐reproductive stage of adults. The relationship between ovarian development and population status of the white‐backed planthopper S ogatella furcifera ( H orváth) and the brown planthopper N ilaparvata lugens ( S tål) was evaluated. Females of both species were captured in rice fields and light traps and then dissected in double‐season rice‐farming regions of southern C hina. The ovarian development of S . furcifera and N . lugens was divided into five levels, following previous studies. The population statuses of both species were examined based on the ovarian development of female adults caught in rice paddies. The ovarian development in N . lugens females caught in light traps mostly ranged from level I to level II , whereas that in S . furcifera females caught in light traps mostly ranged from level I to level III . During peak immigration, ovarian development in N . lugens females was mainly at level II , whereas that in S . furcifera females was mainly at level II and sporadically at level III . During peak emigration, both S . furcifera and N . lugens showed level I ovarian development. The temporal dynamics of ovarian development in light trap catches revealed that (i) significant emigration and partial immigration periods occur in S . furcifera , with ovarian development mainly at level I and sporadically from level II to level III and (ii) numerous immigrants of N . lugens were detected during sedentary and local breeding periods. The temporal dynamics of ovarian development provides more information than does the paddy population. Thus, this study proposes another method for pest forecasting, which is more precise and efficient than conventional forecasting methods such as light trap catching and monitoring population dynamics in rice fields.

Abstract To study the phototactic responses of white‐backed planthopper , S ogatella furcifera ( H orváth) and brown planthopper, N ilaparvata lugens ( S tål) to different wavelengths, four colours of light traps (blue, green, yellow and red light‐emitting diodes) were placed in the same rice field along with a traditional black light trap. This study revealed that S . furcifera and N . lugens are more attracted to blue and green lights than that to yellow and red lights. During the 24 nights, compared with the black light trap, the blue LED trap could catch more rice planthoppers at 17 nights. Furthermore, catches of other species (moths and beetles) were substantially reduced in blue LED light traps. Multiple regression models were developed to assess the effect of weather factors on light trap catches of rice planthoppers. Rainfall and mean air temperature at a night mainly affected light trap catches of S . furcifera . Higher rainfall and lower temperature increased light trap catches of S . furcifera . However, wind speed was the main factor affecting the catches of N . lugens, and the lower incidence of catches was found in the night when wind speed exceeded 3.08 m/s. S. furcifera may be flying against wind at light wind nights by 0.3–1.5 m/s, whereas N. lugens may be flying down at strong wind nights by 1.5–3.08 m/s. Relative humidity did not significantly influence on trap catches. Consequently, light wavelengths, precipitation, average temperature and wind should be considered when monitoring rice planthoppers by light traps. Therefore, the blue LED light traps are worth using for monitoring planthoppers.

1025 Background: DESTINY-Breast03 (NCT03529110), a randomized, multicenter, open-label, phase 3 study, assessed the efficacy and safety of T-DXd vs T-DM1 in pts with HER2+ mBC treated with ≥1 prior anti-HER2 regimen. Median (m) overall survival (OS) was not reached in either arm at the prior data cutoff (DCO; Jul 25, 2022). We report updated survival results, including efficacy and safety, after median duration of follow-up of 41 mo. Methods: Pts were randomized 1:1 to T-DXd 5.4 mg/kg or T-DM1 3.6 mg/kg once every 3 weeks. Primary endpoint was progression-free survival (PFS) by blinded independent central review (assessed at prior DCO); key secondary endpoint was OS. Other secondary endpoints included objective response rate (ORR), PFS, duration of response (DoR), PFS from time of randomization to progression on next line of therapy or death (PFS2), and safety. All secondary endpoints were based on investigator assessment. Results: 524 pts were randomized (T-DXd, n = 261; T-DM1, n = 263). As of Nov 20, 2023, median duration of follow-up was 43.0 mo (range, 0.0-62.9) for T-DXd and 35.4 mo (range, 0.0-60.9) for T-DM1. mOS (95% CI) was 52.6 mo (48.7-not evaluable [NE]) for T-DXd and 42.7 mo (35.4-NE) for T-DM1 (hazard ratio [HR], 0.73), with 110 (42.1%) and 126 (47.9%) OS events, respectively. OS rate (95% CI) at 36 mo was 67.6% (61.3-73.0%; T-DXd) vs 55.7% (49.2-61.7%; T-DM1). mPFS was 29.0 mo for T-DXd and 7.2 mo for T-DM1; PFS rate (95% CI) at 24 mo was 55.8% (49.1-62.0%; T-DXd) vs 20.6% (15.4-26.4%; T-DM1). mPFS2 was 45.2 mo (T-DXd) vs 23.1 mo (T-DM1). Median treatment duration was 18.2 mo (range, 0.7-56.6) with T-DXd vs 6.9 mo (range, 0.7-55.2) with T-DM1; rates of treatment-emergent adverse events (TEAEs) were consistent with prior DCO. Adjudicated drug-related interstitial lung disease/pneumonitis occurred in 16.7% of pts with T-DXd (4 new events [all grade 2] since prior DCO) vs 3.4% with T-DM1 (1 new event [grade 1]); neither arm had grade 4 or 5 events. Key efficacy and safety results are shown in the table. Conclusions: The superiority of T-DXd over T-DM1 was reinforced in this long-term analysis, as observed by clinically meaningful improvement in OS, PFS, and PFS2, consistent with prior DCO. The safety profile of T-DXd continues to be manageable with no cumulative toxicities observed with longer follow-up. Clinical trial information: NCT03529110 . [Table: see text]

Abstract Background In DESTINY-Breast03 (NCT03529110), T-DXd showed statistically significant and clinically meaningful improvement in progression-free survival (PFS) and overall survival (OS) vs T-DM1 in pts with HER2+ mBC previously treated with trastuzumab and a taxane. We report the 5-year follow-up efficacy and safety analysis. Methods DESTINY-Breast03 was a randomized, multicenter, open-label, phase 3 trial. Pts were assigned 1:1 to T-DXd 5.4 mg/kg or T-DM1 3.6 mg/kg intravenously/3 wk. Exploratory analyses at 5 years included PFS, PFS2 (time from randomization to disease progression on the next line of therapy or death), OS, confirmed objective response rate (cORR), duration of response (DOR) (all investigator assessed), and safety. Results Overall, 524 pts were randomized (261 to T-DXd; 263 to T-DM1), with the last pt enrolled on June 23, 2020. At the data cutoff (DCO), June 27, 2025, median (m; range) duration of follow-up was 50.9 mo (0.0-80.6) for T-DXd and 35.4 mo (0.0-80.4) for T-DM1; 24 pts (9.3%) in the T-DXd group and 2 pts (0.8%) in the T-DM1 group remained on treatment. The most common reasons pts discontinued were progressive disease (44.7% T-DXd, 70.9% T-DM1) and adverse events (AEs; 26.8% T-DXd, 10.0% T-DM1). Among pts who discontinued, 161/233 (69.1%) in the T-DXd group and 203/259 (78.4%) in the T-DM1 group received subsequent systemic anticancer therapy. Median (range) treatment duration was 18.2 mo (0.7-76.0) with T-DXd and 6.9 mo (0.7-65.1) with T-DM1. Estimated mPFS (95% CI) was 29.0 mo (23.7, 42.7) with T-DXd vs 7.8 mo (6.8, 8.3) with T-DM1 (hazard ratio [HR], 0.33 [95% CI, 0.26, 0.41]). The estimated PFS (95% CI) rate at 5 years was 37.6% (30.8, 44.4) with T-DXd vs 10.0% (6.1, 15.0) with T-DM1. Estimated mOS (95% CI) was 56.4 mo (49.4, 67.0) with T-DXd vs 42.7 mo (35.4, 52.6) with T-DM1 (HR, 0.74 [95% CI, 0.59, 0.94], using a stratified Cox regression model). The estimated OS (95% CI) rate at 5 years was 48.1% (41.7, 54.2) with T-DXd vs 36.9% (30.8, 43.1) with T-DM1. Rates of treatment-emergent adverse events (TEAEs) were consistent with the prior DCO. Exposure-adjusted incidence rates for any-grade, grade ≥3, and serious TEAEs were lower with T-DXd than T-DM1. Adjudicated drug-related interstitial lung disease (ILD)/pneumonitis occurred in 17.5% of pts treated with T-DXd (2 new events [grade 1 and 3] since last DCO) and 3.1% of pts with T-DM1, with 3 (1.2%) and 1 (0.4%) grade 3 events, respectively, and no grade 4 or 5 in either group. Updated data are shown in the Table. Conclusions The final analysis of DESTINY-Breast03 confirms the superior efficacy of T-DXd over T-DM1 in pts with HER2+ mBC whose disease had progressed following prior treatment with trastuzumab and a taxane. The safety profile of T-DXd was similar to previous reports, with no new safety signals observed with longer follow-up. Citation Format: S.-A. Im, J. Cortes, S.-B. Kim, G. Curigliano, G. Buscacio de Sousa, S. E. Nagai, T. Sun, J. Ignacio Delgado Mingorance, V. Kaklamani, F. Puglisi, C. Levy, H. Iwata, S. A. Hurvitz, S. Nakatani, Z. Liang, S. Ashfaque, A. Egorov, E. P. Hamilton. Trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (mBC): Final analysis from DESTINY-Breast03 [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2025; 2025 Dec 9-12; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2026;32(4 Suppl):Abstract nr PS5-01-30.